Biocon is a global biopharmaceutical company transforming access to healthcare through affordable innovation. Guided by our shared mission, we are focused on delivering lifesaving therapies to patients everywhere.
Biocon Biologics is a leading integrated global biosimilars company with world-class ‘lab to market’ capabilities across development, manufacturing, and marketing. The scientifically validated, high quality human insulin and analog products manufactured at the facility are benefiting millions of patients in Malaysia and other countries.
Biocon is addressing global medical needs through a portfolio of differentiated and high quality, life-saving biotherapeutics. We have used innovative science to bring competition for some of the world’s most expensive medicines through our generics and biosimilars, thus enabling affordable access to advanced therapies for millions of patients with chronic conditions across the globe. At the ...
They represent Biocon’s risk-balanced strategy, underpinned by agile network connections, a robust pipeline and a timely ‘emerging markets’ orientation. We have leveraged India’s value advantage of unmatched scientific talent and cost-competitive manufacturing to deliver scale, speed and quality.
We are a global biopharmaceutical company driven by the belief that everyone, everywhere deserves access to affordable, quality medicines. At Biocon, we pioneer novel approaches to improve patient outcomes today, for a better tomorrow. We constantly find new ways to treat diabetes, cancer and autoimmune diseases to improve the quality of life for an ageing population.
Biocon is a unique global biopharmaceutical company changing patients’ lives in over 120 countries. From drug discovery to drug delivery, we make life-saving medicines for the most feared diseases, to extend and significantly improve the quality of life.
DES MOINES, Iowa, Jan. 7, 2026 /PRNewswire/ -- BioSpace, the leading life sciences news and careers site, has announced its 2026 selections for the industry's most promising up-and-coming companies.